Compare · NTRA vs TRUP
NTRA vs TRUP
Side-by-side comparison of Natera Inc. (NTRA) and Trupanion Inc. (TRUP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRA and TRUP operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $38.87B, about 33.4x TRUP ($1.16B).
- NTRA has been more active in the news (27 items in the past 4 weeks vs 4 for TRUP).
- NTRA has more recent analyst coverage (25 ratings vs 12 for TRUP).
- Company
- Natera Inc.
- Trupanion Inc.
- Price
- -
- -
- Market cap
- $38.87B
- $1.16B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 27
- 4
- Recent ratings
- 25
- 12
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Trupanion Inc.
Trupanion, Inc., together with its subsidiaries, provides medical insurance for cats and dogs on monthly subscription basis in the United States, Canada, Puerto Rico, and Australia. The company operates through Subscription Business and Other Business segments. It serves pet owners and veterinarians. The company was formerly known as Vetinsurance International, Inc. changed its name to Trupanion, Inc. in 2013. Trupanion, Inc. was founded in 2000 and is headquartered in Seattle, Washington.
Latest NTRA
- Director Chapman Rowan E sold $37,101 worth of shares (135 units at $274.82) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 4,663 units (SEC Form 4)
- CO-FOUNDER Sheena Jonathan sold $410,825 worth of shares (1,500 units at $273.88) as part of a pre-agreed trading plan (SEC Form 4)
- Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio
- CO-FOUNDER Sheena Jonathan sold $836,898 worth of shares (3,150 units at $265.68) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 246,202 units (SEC Form 4)
- Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
- EXECUTIVE CHAIRMAN Rabinowitz Matthew sold $280,000 worth of shares (1,000 units at $280.00) as part of a pre-agreed trading plan (SEC Form 4)
- SEC. AND CHIEF LEGAL OFFICER Rabinowitz Daniel sold $4,574,431 worth of shares (16,800 units at $272.29) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 172,294 units (SEC Form 4)
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $818,710 worth of shares (3,000 units at $272.90) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 134,643 units (SEC Form 4)
- Natera Inc. filed SEC Form 8-K: Leadership Update
- Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
Latest TRUP
- Trupanion Announces Second Quarter 2026 Earnings Release and Conference Call
- Chief Operating Officer Gallagher John R sold $10,926 worth of shares (431 units at $25.35) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 32,634 units (SEC Form 4)
- SEC Form 144 filed by Trupanion Inc.
- Trupanion to Participate in Virtual Fireside Chat with Piper Sandler
- Trupanion Announces Winners of the 2026 Veterinary Appreciation Day® Awards
- Trupanion Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- EVP, North Am & Vet Strategy Weinrauch Steve exercised 8,500 shares at a strike of $15.46 and sold $146,828 worth of shares (6,674 units at $22.00), increasing direct ownership by 2% to 78,062 units (SEC Form 4)
- Amendment: SEC Form 4 filed by EVP, Trupanion International Wheeler Simon
- Amendment: SEC Form 4 filed by EVP, Trupanion International Wheeler Simon
- Chief Operating Officer Gallagher John R sold $78,153 worth of shares (3,603 units at $21.69) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 33,065 units (SEC Form 4)